Compare Msci Inc (MSCI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Msci Inc trades at $562.95 (market cap $45.51B), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Msci Inc pays the higher dividend (1.31%). Which is the better fit depends on your goals.
| MSCI | REGN | |
|---|---|---|
Market Cap | $45.51B | $70.47B |
Sector | Financials | Health |
52-Week High | $643.83 | $812.27 |
52-Week Low | $511.84 | $545.46 |
Enterprise Value | $51.67B | $64.42B |
Dividend Yield | 1.31% | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
